Download PDF
February 19, 2013

B2PAC, SCD-iBIO Form Alliance to Advance Commercialization of Industrial Biotechnology

Lynn L. Bergeson

The Biobased Products Advocacy Consortium (B2PAC), an affiliate of Bergeson & Campbell, P.C. (B&C), and the Society for the Commercial Development of Industrial Biotechnology (SCD-iBIO), an affiliate of the Society of Chemical Manufacturers & Affiliates (SOCMA), announced on February 14, 2013, the formation of a new alliance to advance the commercialization of industrial biotechnology and biobased products. According to a recently released report from Lux Research, industrial biotechnology and biobased product development is experiencing a robust year in growth of 30%. Through a memorandum of understanding, B2PAC and SCD-iBIO have recognized the complementary nature of their missions and the benefit to the biobased chemical and industrial biotechnology communities of working cooperatively where appropriate.

“Our joint membership is enjoying unprecedented success in commercializing their products,” noted Lynn L. Bergeson, Managing Partner of B&C. “Our regulatory challenges are many, but so are our opportunities for advocacy and legislative relief. Our legal and advocacy firepower coupled with SCD-iBIO’s depth and technical skills has made our alliance a formidable force — businesses in this space are urged to join and benefit from our unique strengths in areas directly impacting commercialization potential.”

Contact Heidi Brown Lewis.